Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson's disease

Neurochemistry International

Volumn 43, Issue 2, 2003, Pages 129-135

  Gibson, G E ^a   Kingsbury, A E ^b   Xu, H ^a   Lindsay, J G ^c   Daniel, S ^b   Foster, O J F ^b   Lees, A J ^b   Blass, J P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Oxidative stress; Parkinson's disease; Ketoglutarate dehydrogenase

Indexed keywords

BRAIN ENZYME; GLUTAMATE DEHYDROGENASE; MITOCHONDRIAL ENZYME; OXOGLUTARATE DEHYDROGENASE; PROTEIN SUBUNIT;

ADULT; AGE; ARTICLE; BRAIN MITOCHONDRION; BRAIN REGION; CADAVER; CEREBELLUM; CITRIC ACID CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFECT; FEMALE; HUMAN; HUMAN TISSUE; MALE; NERVE DEGENERATION; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; SEX RATIO; TISSUE PRESERVATION;

EID: 0344838535     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(02)00225-5     Document Type: Article

References (40)

1. Albers D.S., Beal M.F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural. Transm. Suppl. 59:2000;133-154.
2. Albers D.S., Augood S.J., Park L.C., Browne S.E., Martin D.M., Adamson J., Hutton M., Standaert D.G., Vonsattel J.P., Gibson G.E., Beal M.F. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J. Neurochem. 74:2000;878-881.
3. Butterworth R.F., Besnard A.M. Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer's disease. Metab. Brain. Dis. 5:1990;179-184.
4. Cassarino D.S., Bennett J.P. Jr. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res. Brain Res. Rev. 29:1999;1-25.
5. Chandrasekaran K., Hatanpaa K., Brady D.R., Stoll J., Rapoport S.I. Downregulation of oxidative phosphorylation in Alzheimer disease: loss of cytochrome oxidase subunit mRNA in the hippocampus and entorhinal cortex. Brain Res. 796:1998;13-19.
6. Cohen G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann. N. Y. Acad. Sci. 899:2000;112-120.
7. Deuschl G., Wilms H., Krack P., Wurker M., Heiss W.D. Function of the cerebellum in Parkinsonian rest tremor and Holmes' tremor. Ann. Neurol. 46:1999;126-128.
8. Dexter D.T., Carayon A., Vidailhet M., Ruberg M., Agid F., Agid Y., Lees A.J., Wells F.R., Jenner P., Marsden C.D. Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55:1990;16-20.
9. Fukuda M., Mentis M., Ghilardi M.F., Dhawan V., Antonini A., Hammerstad J., Lozano A.M., Lang A., Lyons K., Koller W., Ghez C., Eidelberg D. Functional correlates of pallidal stimulation for Parkinson's disease. Ann. Neurol. 49:2001a;155-164.
10. Fukuda M., Mentis M.J., Ma Y., Dhawan V., Antonini A., Lang A.E., Lozano A.M., Hammerstad J., Lyons K., Koller W.C., Moeller J.R., Eidelberg D. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. Brain. 124:2001b;1601-1609.
11. Gibson G.E., Sheu K.F., Blass J.P., Baker A., Carlson K.C., Harding B., Perrino P. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch. Neurol. 45:1988;836-840.
12. Gibson G.E., Park L.C., Sheu K.F., Blass J.P., Calingasan N.Y. The alpha-ketoglutarate dehydrogenase complex in neurodegeneration. Neurochem. Int. 36:2000;97-112.
13. Gu M., Owen A.D., Toffa S.E., Cooper J.M., Dexter D.T., Jenner P., Marsden C.D., Schapira A.H. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J. Neurol. Sci. 158(1):1998;24-29.
14. Hanakawa T., Katsumi Y., Fukuyama H., Honda M., Hayashi T., Kimura J., Shibasaki H. Mechanisms underlying gait disturbance in Parkinson's disease: a single photon emission computed tomography study. Brain. 122:1999;1271-1282.
15. Hardy J.A., Wester P., Winblad B., Gezelius C., Bring G., Eriksson A. The patients dying after long terminal phase have acidotic brains: implications for biochemical measurements on autopsy tissue. J. Neural. Transm. 61:1985;253-264.
16. Hattori N., Tanaka M., Ozawa T., Mizuno Y. Immunohistochemical studies on complexes I, II, and IV of mitochondria in Parkinson's disease, and IV of mitochondria in Parkinson's disease. Ann. Neurol. 30:1991;563-571.
17. Joffe G.T., Parks J.K., Parker W.D. Jr. Secondary inhibition of 2-ketoglutarate dehydrogenase complex by MPTP. NeuroReport. 9:1998;2781-2783.
18. Kingsbury A.E., Foster O.J., Nisbet A.P., Cairns N., Bray L., Eve D.J., Lees A.J., Marsden C.D. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res. Mol. Brain Res. 28:1995;311-318.
19. Kingsbury A.E., Bray E.L., Foster O.J. A simplified and rapid procedure for in situ hybridization on human, flash-frozen, post-mortem brain and its combination with immunohistochemistry. J. Neurosci. Methods. 69:1996;213-227.
20. Kingsbury, A.E., Elliott, L., Foster, O.J.F., 1999. Altered Purkinje neuron metabolism in MSA and PD. In: Proceedings of the XIII International Congress on Parkinson's Disease, Vancouver, Canada.
21. Kingsbury A.E., Cooper M., Schapira A.H., Foster O.J. Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: an in situ hybridization study. Ann. Neurol. 50:2001;142-149.
22. Kish S.J., Shannak K.S., Rajput A.H., Gilbert J.J., Hornykiewicz O. Cerebellar norepinephrine in patients with Parkinson's disease and control subjects. Arch. Neurol. 41:1984;612-614.
23. Kobayashi T., Matsumine H., Matuda S., Mizuno Y. Association between the gene encoding the E2 subunit of the alpha-ketoglutarate dehydrogenase complex and Parkinson's disease. Ann. Neurol. 43:1998;120-123.
24. Lai J.C., Sheu K.F., Kim Y.T., Clarke D.D., Blass J.P. The subcellular localization of glutamate dehydrogenase (GDH): Is GDH a marker for mitochondria in brain? Neurochem. Res. 11:1986;733-744.
25. Loeffler D.A., LeWitt P.A., Juneau P.L., Camp D.M., Arnold L.A., Hyland K. Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation. Brain Res. Bull. 47:1998;663-667.
26. Mastrogiacomo F., Bergeron C., Kish S.J. Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. J. Neurochem. 61:1993;2007-2014.
27. Mastrogiacomo F., LaMarche J., Dozic S., Lindsay G., Bettendorff L., Robitaille Y., Schut L., Kish S.J. Immunoreactive levels of alpha-ketoglutarate dehydrogenase subunits in Friedreich's ataxia and spinocerebellar ataxia type 1. Neurodegeneration. 5:1996;27-33.
28. McNaught K.S., Altomare C., Cellamare S., Carotti A., Thull U., Carrupt P.A., Testa B., Jenner P., Marsden C.D. Inhibition of alpha-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). NeuroReport. 6:1995;1105-1108.
29. Mizuno Y., Matuda S., Yoshino H., Mori H., Hattori N., Ikebe S. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann. Neurol. 35:1994;204-210.
30. Mizuno Y., Ikebe S., Hattori N., Nakagawa-Hattori Y., Mochizuki H., Tanaka M., Ozawa T. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochim. Biophys. Acta. 1271:1995;265-274.
31. Park L.C.H., Zhang H., Sheu K.F., Calingasan N.Y., Kristal B.S., Lindsay J.G., Gibson G.E. Metabolic impairment induces oxidative stress, compromises inflammatory responses, and inactivates a key mitochondrial enzyme in microglia. J. Neurochem. 72:1999;1948-1958.
32. Park L.C.H., Albers D.S., Xu H., Lindsay J.G., Beal M.F., Gibson G.E. Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy. J. Neurosci. Res. 66:2001;1028-1034.
33. Parker W.D. Jr., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-723.
34. Schapira, A.H.V., 1997. Mitochondrial dysfunction and oxidative damage in Parkinson's disease. In: Beal, M.F., Nowell, N., Bodis-Wollner, I. (Eds.), Mitochondria & Free Radicals in Neurodegenerative Disease. Wiley, New York, pp. 343-360.
35. Schapira A.H.V., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:1990;823-827.
36. Schoonen W.G., Wanamarta A.H., van der Klei-van Moorsel J.M., Jakobs C., Joenje H. Hyperoxia-induced clonogenic killing of HeLa cells associated with respiratory failure and selective inactivation of Krebs cycle enzymes. Mutat. Res. 237:1990;173-181.
37. Shen X.M., Li H., Dryhurst G. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the alpha-ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease. J. Neural Transm. 107:2000;959-978.
38. Sheu K.F., Calingasan N.Y., Lindsay J.G., Gibson G.E. Immunochemical characterization of the deficiency of the alpha-ketoglutarate dehydrogenase complex in thiamine-deficient rat brain. J. Neurochem. 70:1998;1143-1150.
39. Tang, J., Haroutunian, V., Xu, X., Davis, K.L., Smith, T.E., Blass, J.P., Gibson, G.E., 2001. Mitochondrial enzymes in schizophrenia. In: Proceedings of the American Psychiatric Association Meeting, New Orleons, LA, p. 36.
40. Terwel D., Bothmer J., Wolf E., Meng F., Jolles J. Affected enzyme activities in Alzheimer's disease are sensitive to antemortem hypoxia. J. Neurol. Sci. 161:1998;47-56.